Quick Answer
X4 Pharmaceuticals, Inc reported Cash And Cash Equivalents At Carrying Value of $217.05 million for the year ending 2025.
- X4 Pharmaceuticals, Inc showed an increase of +289.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $2.28 million | Q2 2017: $24.14 million | Q3 2017: $26.25 million | Q1 2018: $64.00 million | Q2 2018: $12.57 million | Q3 2018: $9.84 million | Q1 2019: $22.30 million | Q2 2019: $90.18 million | Q3 2019: $76.25 million | Q1 2020: $115.05 million | Q2 2020: $103.74 million | Q3 2020: $88.81 million | Q1 2021: $114.95 million | Q2 2021: $95.16 million | Q3 2021: $76.39 million | Q1 2022: $66.43 million | Q2 2022: $47.38 million | Q3 2022: $79.86 million | Q1 2023: $93.41 million | Q2 2023: $136.43 million | Q3 2023: $131.58 million | Q1 2024: $60.49 million | Q2 2024: $147.22 million | Q3 2024: $97.41 million | Q1 2025: $40.26 million | Q2 2025: $39.22 million | Q3 2025: $69.63 million.
- Over the full 10 years of available data (2016 to 2025), X4 Pharmaceuticals, Inc's Cash And Cash Equivalents At Carrying Value has grown by 1,331.7%.
- Historical annual values: Fiscal year 2025: $217.05 million | Fiscal year 2024: $55.70 million | Fiscal year 2023: $99.22 million | Fiscal year 2022: $121.72 million | Fiscal year 2021: $81.79 million | Fiscal year 2020: $78.71 million | Fiscal year 2019: $126.18 million | Fiscal year 2018: $8.13 million | Fiscal year 2017: $26.68 million | Fiscal year 2016: $15.16 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: